undamentalytics Newsletter
Sign in

Arcus Biosciences, Inc. revenue

Arcus Biosciences, Inc.'s revenue was $247m in fiscal 2025, down 4.3% on the year before. Since fiscal 2017 ($1.4m) it has grown at a compound 90.7% a year. Over the last twelve months it was $117m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue181578383112117258247117
Growth on the year before—+491.2%+79.6%+420.0%+391.0%−70.8%+4.5%+120.5%−4.3%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
License and Development Services $221M 89.5% ▼ 0.5%
Other Collaboration Revenue $26M 10.5% ▼ 27.8%

From Arcus Biosciences, Inc.'s 10-K filed February 25, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Arcus Biosciences, Inc. $117m -55.3% -1.1%
ARS Pharmaceuticals, Inc. $117m 4.1% 711.3%
Mesoblast LTD $120m 599.2% —
Xencor Inc $105m -28.6% -2.5%
Agenus Inc $133m 30.5% 10.1%
Kymera Therapeutics, Inc. $102m 133.8% 29.7%

Compare with peers

Head to head: RCUS vs SPRYMESO vs RCUSRCUS vs XNCRAGEN vs RCUS

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Arcus Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Arcus Biosciences, Inc.